Articles from One04 Therapeutics

FREIBURG, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- One04 Therapeutics GmbH & Co. KG, a clinical-stage biopharmaceutical company developing CPV-104, a first-in-class, recombinant, full-length human Factor H therapy, today reported positive interim data from the ongoing Phase 1 study of CPV-104 in patients with C3 glomerulopathy (C3G). The data are being presented in a late-breaking poster at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.

Freiburg, Germany, October 6, 2026 – One04 Therapeutics GmbH & Co. KG, a clinical-stage biopharmaceutical company developing CPV-104, a first-in-class, recombinant, full-length human Factor H therapy, today announced the acceptance of a late-breaking poster presenting positive interim data from the ongoing Phase 1 study of CPV-104 at the American Society of Nephrology (ASN) Kidney Week, taking place October 21-25, 2026, in Denver, Colorado.

Freiburg, Germany, September 15, 2026 – One04 Therapeutics GmbH & Co. KG today announced its launch as a clinical-stage biopharmaceutical company with encouraging Phase 1 results for CPV-104, a first-in-class, full-length recombinant human Factor H candidate with disease-modifying potential across a broad range of complement-mediated diseases.